专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明公开

EP2274003A4 COMPOSITION AND METHOD FOR THE INHIBITION OF POSTOPERATIVE ADHESIONS SEVERITY 有权转让
标题翻译：组合物和方法以减少重术后粘连
公开(公告)号：EP2274003A4
公开(公告)日：2012-04-25
申请号：EP09725636
申请日：2009-03-19
申请人： BRANDAO JACKSON LOPES , DALLAN LUIS ALBERTO OLIVEIRA , FUNDACAO SAO FRANCISCO XAVIER
发明人： DALLAN LUIS ALBERTO OLIVEIRA , LOPES JACKSON BRANDAO
IPC分类号： A61K38/18 , A61K31/722 , A61P41/00
CPC分类号： A61K38/18 , A61K31/722 , A61K38/1808 , A61K38/1825 , A61K38/1833 , A61K47/36 , C07K14/475

62. 发明授权

EP1830856B1 PREVENTING PATHOLOGICAL INCREASES IN THE RATE OF NERVE CELL SUICIDE IN IMMATURE NERVOUS SYSTEMS 有权
标题翻译：阻止神经细胞自杀率增加了病理未成熟神经系统
公开(公告)号：EP1830856B1
公开(公告)日：2012-04-18
申请号：EP05782582.0
申请日：2005-08-02
申请人： Olney, John W.
发明人： Olney, John W.
IPC分类号： A61K31/02 , A61P25/00 , A61P23/00 , A61K45/06 , A61K33/00 , A61P39/00 , A61P41/00
CPC分类号： A61K45/06 , A61K31/5513 , A61K33/00 , A61K2300/00
摘要： A method for preventing pediatric and obstetric medical drugs from triggering apoptotic neurodegeneration in an immature nervous system is disclosed. The method comprises coadministration of (1) a drug that has been shown in in vivo tests to trigger apoptotic neurodegeneration in unprotected neonatal mammals and (2) a drug the enters the mammalian central nervous system and stimulates neuronal activity to prevent neuroapoptosis. Examples of the first group of drugs include drugs that suppress activity at the NMDA subclass of glutamate receptors and promote inhibitory transmission through at least one class of GABA receptors. Examples of the second drug include, lithium and xenon.

63. 发明公开

EP2411021A2 METHOD FOR SUPPRESSING OR PREVENTING FIBROUS ADHESION FORMATION USING A MULTICOMPONENT AQUEOUS OXYCHLORINE COMPOSITION PREPARED ON-SITE 审中-公开
标题翻译：利用现场制备的多组分水性氯氧化物组合物抑制或防止纤维粘合剂形成的方法
公开(公告)号：EP2411021A2
公开(公告)日：2012-02-01
申请号：EP10756641.6
申请日：2010-03-19
申请人： Kross-Link Laboratories, Inc.
发明人： KROSS, Robert, D. , VILLANUEVA, Cleva
IPC分类号： A61K33/40 , A61K33/20 , A61K33/14 , A61P41/00
CPC分类号： A61K33/20 , A61K9/0019 , A61K33/00 , A61K33/14 , A61K33/40 , A61K45/06 , A61K47/12 , A61K2300/00
摘要： A composition and method are described for suppressing or preventing fibrous adhesion formation using a multicomponent aqueous oxychlorine composition. Fibrous adhesions typically form during healing of tissue, for example following a surgical procedure. A multicomponent oxychlorine composition is provided for irrigating the tissue which minimizes post-surgical adhesion formation, the composition containing both chlorine dioxide and chlorite ion, and a complex ion thereof. The chlorine dioxide level generally is in an effective range of CIO2 concentration from about 10 ppm to a maximum of about 110 ppm. In a preferred embodiment, a physiological composition is provided in a thickened form to increase retention in the area being treated. The composition is preferably based on a standard saline solution converted to the oxychlorine composition just prior to use by sequential addition of aqueous concentrates of a chlorite salt, a hypochlorite salt combined with a physiological buffer-producing salt of a multibasic acid, and an acidifying agent, optionally including a thickening agent.
摘要翻译：描述了使用多组分含水氧氯化物组合物抑制或防止纤维粘附形成的组合物和方法。纤维粘连通常在组织愈合期间形成，例如在手术过程之后。提供多组分氯氧化物组合物用于灌注组织，其使手术后粘附形成最小化，所述组合物含有二氧化氯和亚氯酸根离子以及其络合离子。二氧化氯水平通常处于从约10ppm至最大约110ppm的CIO 2浓度的有效范围内。在一个优选的实施方案中，以增稠形式提供生理组合物以增加待治疗区域的滞留。该组合物优选基于标准盐水溶液，其在即将使用之前通过依次加入亚氯酸盐的水性浓缩物，与产生生理缓冲液的多元酸盐结合的次氯酸盐和酸化剂，任选地包含增稠剂。

64. 发明公开

EP2400963A1 COMPOSITIONS FOR USE IN CARDIOPLEGIA COMPRISING ESMOLOL AND ADENOSINE 有权转让
标题翻译： ZUSAMMENSETZUNGEN ENARALTEND ESMOLOL UND ADENOSINE ZUR VERWENDUNG in KARDIOPLEGIE
公开(公告)号：EP2400963A1
公开(公告)日：2012-01-04
申请号：EP10709760.2
申请日：2010-02-26
申请人： King's College London
发明人： FALLOUH, Hazem, B. , KENTISH, Jonathan, C. , CHAMBERS, David, J.
IPC分类号： A61K31/24 , A61K31/7076 , A61K45/06 , A61P41/00
CPC分类号： A61K31/7076 , A61K9/08 , A61K31/216 , A61K31/24 , A61K33/06 , A61K2300/00
摘要： The invention related to a composition for use in cardioplegia, said composition comprising (i) esmolol; and (ii) adenosine, wherein in use the concentration of said esmolol is in the range 0.3-1.5 mM, and wherein in use the concentration of said adenosine is in the range 0.1-1.5 mM. The invention also relates to methods of making and using such compositions.
摘要翻译：本发明涉及用于心麻痹的组合物，所述组合物包含（i）艾司洛尔; 和（ii）腺苷，其中在使用中所述艾司洛尔的浓度在0.3-1.5mM范围内，并且其中在使用中所述腺苷的浓度在0.1-1.5mM的范围内。本发明还涉及制备和使用这些组合物的方法。

65. 发明公开

EP2291197A4 USE OF HISTAMINE H4 ANTAGONIST FOR THE TREATMENT OF POST-OPERATIVE ADHESIONS 失效转让
标题翻译：组胺H4拮抗剂术后粘连的治疗
公开(公告)号：EP2291197A4
公开(公告)日：2011-10-26
申请号：EP09763577
申请日：2009-06-11
申请人： JANSSEN PHARMACEUTICA NV
发明人： THURMOND ROBIN L , WADSWORTH SCOTT A
IPC分类号： A61K31/404 , A61K31/407 , A61K31/4164 , A61K31/4178 , A61K31/4184 , A61K31/423 , A61K31/428 , A61K31/44 , A61K31/4439 , A61K31/496 , A61K31/497 , A61K31/498 , A61K31/505 , A61K31/506 , A61K31/519 , A61K31/53 , A61K45/06 , A61P41/00
CPC分类号： A61K31/506 , A61K31/496 , A61K31/497 , A61K45/06 , A61L31/16 , A61L2300/432 , A61L2300/436 , A61K2300/00
摘要： The present invention includes methods for the inhibition of post-operative adhesion formation between tissue surfaces in a body cavity having been subjected to a surgical procedure, which methods involve administering a histamine H4 receptor antagonist, systemically, directly to tissue surfaces in the body cavity, or both, and to delivery vehicles and compositions suitable for use for local, non-systemic administration of a drug to the body and directly to tissue within a body cavity having been subjected to a surgical procedure. The drug is selected from the group consisting of benzoimidazol-2-yl pyrimidines and pyrazines.

66. 发明公开

EP2376073A2 DERMAL APPLICATION OF VASOCONSTRICTORS 审中-公开
标题翻译：增殖膜的皮肤应用
公开(公告)号：EP2376073A2
公开(公告)日：2011-10-19
申请号：EP09829849.0
申请日：2009-11-30
申请人： Zachar, Oron
发明人： Zachar, Oron
IPC分类号： A61K31/137 , A61P41/00
CPC分类号： A61K45/06 , A61K31/00 , A61K31/137
摘要： There is disclosed the topical dermal use of vasocontrictor substances for regulating body temperature to treat, prevent or delay the onset of anesthetic induced hypothermia. Kits containing appropriate materials and instructions, and other embodiments, are also disclosed.
摘要翻译：公开了用于调节体温的血管收缩剂物质的局部皮肤用途，以治疗，预防或延迟麻醉诱导的低体温的发作。还公开了包含适当材料和说明的试剂盒以及其他实施方案。

67. 发明授权

EP1713480B1 THE USE OF QUATERNARY PYRIDINIUM SALTS AS VASOPROTECTIVE AGENTS 有权转让
标题翻译：季吡啶作为血管保护产品使用
公开(公告)号：EP1713480B1
公开(公告)日：2011-09-14
申请号：EP05726215.6
申请日：2005-01-07
申请人： Pharmena SA
发明人： GEBICKI, Jerzy , CHLOPICKI, Stefan
IPC分类号： A61K31/4425 , A61P1/04 , A61P1/16 , A61P3/04 , A61P3/10 , A61P9/00 , A61P9/10 , A61P9/12 , A61P11/00 , A61P15/10 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/00 , A61P41/00
CPC分类号： A61K31/455 , A23L33/30 , A61K9/0053 , A61K9/007 , A61K31/4406 , A61K31/4425
摘要： The invention relates to the use of quaternary pyridinium salts of formula (1), wherein wherein R is NH2, CH3, or N(H)CH2OH group, and X is pharmaceutically acceptable counterion, for the preparation of vasoprotective agent for the treatment or prevention of conditions or diseases associated with dysfunction of vascular endothelium, oxidative stress, and/or insufficient production of endothelial prostacyclin PGI2, in particular but not exclusively if the above coincides with hypercholes terolemia, hypertriglyceridemia or low HDL level.

68. 发明公开

EP2295541A1 Pluripotent stem cell derived from cardiac tissue 有权
标题翻译： Aus Herzgewebe abgeleitete pluripotente Stammzellen
公开(公告)号：EP2295541A1
公开(公告)日：2011-03-16
申请号：EP10179375.0
申请日：2006-03-03
申请人： Kyoto University
发明人： Oh, Hidemasa , Tateishi, Kento , Matsubara, Hiroaki
IPC分类号： C12N5/074 , A61K35/34 , A61P9/00 , A61P41/00 , A61P43/00 , A61L27/00
CPC分类号： A61K35/34 , A61K35/12 , A61L27/3873 , A61L27/3895 , A61L2430/20 , C12N5/0607 , C12N5/0661 , C12N5/0662 , C12N5/0668 , C12N5/0691 , C12N2501/11 , C12N2501/115 , C12N2501/70 , C12N2506/03 , C12N2506/1315
摘要： An object of the present invention is to provide a stem cell applicable to regenerative therapeutic method, and to provide a technique to carry out regenerative therapy using the cell. A collected cardiac tissue fragment is enzymatically treated to prepare a cell suspension. Then using the cell suspension, following steps are carried out: (1) separation of cells by the density gradient method, (2) suspension-culture in a culture medium containing fibroblast growth factor and epidermal growth factor and (3) selection and separation of cells forming a floating sphere to obtain pluripotent stem cells. Thus-obtained pluripotent stem cells are used to carry out regenerative therapy.
摘要翻译：本发明的目的在于提供一种适用于再生治疗方法的干细胞，提供使用该细胞进行再生治疗的技术。收集的心脏组织片段进行酶处理以制备细胞悬浮液。然后使用细胞悬浮液，进行以下步骤：（1）通过密度梯度法分离细胞，（2）在含有成纤维细胞生长因子和表皮生长因子的培养基中悬浮培养，（3）选择和分离形成浮球以获得多能干细胞的细胞。这样获得的多能干细胞用于进行再生治疗。

69. 发明公开

EP2279738A1 The use of quaternary pyridinium salts as vasoprotective agents 审中-公开
标题翻译： Verwendung vonQuaternärenPyridiniumverbindungen zum schutz derGefässe
公开(公告)号：EP2279738A1
公开(公告)日：2011-02-02
申请号：EP10180501.8
申请日：2005-01-07
申请人： Pharmena SA
发明人： Gebicki, Jerzy , Chlopicki, Stefan
IPC分类号： A61K31/4425 , A61P1/04 , A61P1/16 , A61P3/04 , A61P3/10 , A61P9/00 , A61P9/10 , A61P9/12 , A61P11/00 , A61P15/10 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/00 , A61P41/00
CPC分类号： A61K31/455 , A23L33/30 , A61K9/0053 , A61K9/007 , A61K31/4406 , A61K31/4425
摘要： The invention relates to the use of quaternary pyridinium salts of formula I, wherein wherein R is NH 2 , CH 3 , or N(H)CH 2 OH, and X- is a pharmaceutically acceptable counterion, for the preparation of vasoprotective agent or a dietary supplement for the treatment or prevention of conditions or diseases associated with dysfunction of vascular endothelium, oxidative stress, and/or insufficient production of endothelial prostacyclin PGI 2 , in particular but not exclusively if the above coincides with hypercholesterolemia, hypertriglyceridemia or low HDL level.
摘要翻译：本发明涉及式I的季吡啶盐的用途，其中R为NH 2，CH 3或N（H）CH 2 OH，X为药学上可接受的抗衡离子，用于制备血管保护剂或用于治疗或预防与血管内皮功能障碍，氧化应激和/或内皮前列环素PGI 2的生产不足有关的病症或疾病的膳食补充剂，特别但不排他地如果上述与高胆固醇血症，高甘油三酯血症或低HDL水平重合。

70. 发明公开

EP2253321A1 Collyrium for the treatment of conial cornea with "cross-linking" trans-epithelial technique 审中-公开
标题翻译： on on on。。。。。。。。。。。。。。。。。。。。
公开(公告)号：EP2253321A1
公开(公告)日：2010-11-24
申请号：EP09006166.4
申请日：2009-05-06
申请人： Pinelli, Roberto
发明人： Pinelli, Roberto
IPC分类号： A61K31/525 , A61K31/14 , A61K45/06 , A61P27/02 , A61P41/00
CPC分类号： A61K9/08 , A61K9/0048 , A61K31/14 , A61K31/525 , A61K33/14 , A61K45/06 , A61K47/06 , A61K2300/00
摘要： Collyrium for the treatment for patients suffering from conical cornea containing the riboflavin photosensitising substance and a surface-active agent to assist penetration of the collyrium in the corneal epithelium; compared with normal collyria for the treatment of conical cornea, the product according to the invention has the advantage of not requiring the removal of the corneal epithelium, with the absence of pain for the patient, who does not need particular post treatment therapy, no longer complains of edema due to the removal of the epithelium and preserves the original corneal transparency.
摘要翻译：用于治疗患有含有核黄素光敏物质的锥形角膜的患者的阴道镜和用于辅助角膜上皮细胞浸润的表面活性剂; 与正常的collyria相比，用于治疗圆锥角膜，根据本发明的产品具有不需要去除角膜上皮的优点，对于不需要特殊治疗后治疗的患者，没有疼痛，不再需要抱怨因去除上皮而引起的水肿，并保留原来的角膜透明度。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式